Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium (68Ga) gozetotide - RadioMedix

Next Previous
X
Search
Drug Profile

Gallium (68Ga) gozetotide - RadioMedix

Alternative Names: (68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; (68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC; (68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; (68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; (68Ga)PSMA-HBED-CC; 68Ga-DKFZ-PSMA-11; 68Ga-HBED-CC-PSMA; 68Ga-HBED-PSMA; 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; 68Ga-PSMA; 68Ga-PSMA HBED-PET/CT; 68Ga-PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-PSMA-11; 68Ga-PSMA-HBED-CC; 68Ga-PSMA-ligand; [68Ga] Prostate-specific Membrane Antigen 11; [68Ga]GaPSMA-11; Ga PSMA; Ga-68 labeled DKFZ-PSMA-11; Ga-68 labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; Ga-68 labeled Glu-urea-Lys(Ahx)-HBED-CC; Ga-68 labeled PSMA-11; Ga-68 labeled PSMA-11 PET; Ga-68-PSMA-11; Gallium Ga 68 PSMA-11; Gallium Ga 68-labeled PSMA-11; Gallium Ga-labeled PSMA-11; Gallium-68 labeled PSMA-11; Gallium-68 PSMA; Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; ProstaMedix; PSMA-HBED-CC GA-68

Latest Information Update: 28 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RadioMedix
  • Developer Chang Gung Memorial Hospital; First Affiliated Hospital of Fujian Medical University; Friedrich-Alexander-University Erlangen-Nuremberg; German Cancer Research Center; Indiana University; Institut de Cancerologie de l'Ouest; Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori; Jewish General Hospital; Mayo Clinic; Medical University of Vienna; National Cancer Institute (USA); Princess Alexandra Hospital; UCLAs Jonsson Comprehensive Cancer Center; University Medical Center Groningen; University of California at San Francisco; University of Zurich
  • Class Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Prostate cancer
  • Phase II Adenoid cystic carcinoma; Renal cell carcinoma; Solid tumours; Thyroid cancer
  • Phase I/II Liver cancer
  • No development reported Bladder cancer; Cancer; Ovarian cancer

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in Bladder-cancer in Austria
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Cancer(Diagnosis, In the elderly, In adults) in China (IV, Injection)
  • 02 Jun 2023 Efficacy data from a diagnostics study in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top